logo-loader
viewBioLargo, Inc.

BioLargo subsidiary Clyra Medical names new CRO and business development head

Shawn Dougherty will serve as chief revenue officer with John Sirpilla taking over as chief business development officer

BioLargo, Inc. - BioLargo subsidiary Clyra Medical names new CRO and business development head
Their appointments come as BioLargo launches the Clyraguard spray to help protect personal protective equipment from the SARS-CoV-2 virus

BioLargo Inc (OTCQB:BLGO) subsidiary Clyra Medical Technologies Inc has recruited two experienced business executives as it launches the Clyraguard personal protection spray to help protect non-critical personal protective equipment from the SARS-CoV-2 virus which causes the COVID-19 disease. 

Shawn Dougherty will serve as chief revenue officer with John Sirpilla taking over as chief business development officer, the company said in a statement Tuesday.

Dougherty is an entrepreneur with substantial experience growing sales and revenues for new and innovative products. Prior to joining Clyra, she co-founded mophie, the number one selling battery case manufacturer for mobile devices in North America. As COO and founder, she helped mophie create the first juice pack battery case for the iPhone in North America and built an exclusive partnership with Apple Inc (NASDAQ:AAPL). 

READ: BioLargo says subsidiary's Clyraguard protective spray inactivates SARS-CoV-2 virus in lab tests

Sirpilla is the former president of Camping World Accessory Stores, a 140-store nationwide retail chain serving the RV industry and was promoted in 2012 to chief business development officer for the parent company, Camping World and Good Sam with annual sales of nearly $4 billion.  He is currently the CEO and founder of Encourage LLC, a family office focused on driving change in healthy living, leadership, and child adoption.

Clyraguard is a personal protective spray designed to help frontline healthcare workers prevent cross-contamination of their personal protective equipment from SARS-CoV-2, the virus that causes COVID-19.

The product is colorless and odorless and has been found to be non-toxic, non-irritating, non-sensitizing and non-staining. Testing at the Galveston National Laboratory at the University of Texas Medical Branch found the spray completely inactivates the SARS-CoV-2 virus.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: BioLargo, Inc.

Price: 0.1925 USD

OTCMKTS:BLGO
Market: OTCQB
Market Cap: $34.09 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioLargo, Inc. named herein, including the promotion by the Company of BioLargo, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

BioLargo completes prototype for PFAS treatment system, ready for pilot testing

BioLargo (OTCQB: BLGO) CEO Dennis Calvert Calvert joined Steve Darling from Proactive with news the company has completed manufacturing on its first prototype unit of their patented BioLargo AEC to tackle PFAS contamination. Calvert told Proactive the next step and he also told investors...

3 days, 22 hours ago

2 min read